Cargando…

Dissecting Vancomycin-Intermediate Resistance in Staphylococcus aureus Using Genome-Wide Association

Vancomycin-intermediate Staphylococcus aureus (VISA) is currently defined as having minimal inhibitory concentration (MIC) of 4–8 µg/ml. VISA evolves through changes in multiple genetic loci with at least 16 candidate genes identified in clinical and in vitro-selected VISA strains. We report a whole...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alam, Md Tauqeer, Petit, Robert A., Crispell, Emily K., Thornton, Timothy A., Conneely, Karen N., Jiang, Yunxuan, Satola, Sarah W., Read, Timothy D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040999/ https://www.ncbi.nlm.nih.gov/pubmed/24787619 http://dx.doi.org/10.1093/gbe/evu092

Ejemplares similares

Effect of genetic background on the evolution of Vancomycin-Intermediate Staphylococcus aureus (VISA)
por: Su, Michelle, et al.
Publicado: (2021)

Development of an Amplicon Nanopore Sequencing Strategy for Detection of Mutations Conferring Intermediate Resistance to Vancomycin in Staphylococcus aureus Strains
por: Moller, Abraham G., et al.
Publicado: (2023)

272 Characteristics of USA500/Iberian Methicillin-Resistant Staphylococcus aureus (MRSA) Invasive Disease
por: Melendez, Andre G., et al.
Publicado: (2014)

Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus
por: Hu, Qiwen, et al.
Publicado: (2016)

Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea
por: Park, Jung Wan, et al.
Publicado: (2019)

Emergence of Vancomycin-Intermediate Staphylococcus aureus and S. sciuri, Greece
por: Tsakris, Athanassios, et al.
Publicado: (2002)

Draft Genome Sequences of Vancomycin-Susceptible Staphylococcus aureus Related to Heterogeneous Vancomycin-Intermediate S. aureus
por: Ramaraj, Thiruvarangan, et al.
Publicado: (2014)

Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates
por: Zhang, Shanshan, et al.
Publicado: (2015)

Reconstruction of the Vancomycin-Susceptible Staphylococcus aureus Phenotype From a Vancomycin-Intermediate S. aureus XN108
por: Peng, Huagang, et al.
Publicado: (2018)

Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus
por: Katayama, Yuki, et al.
Publicado: (2016)

Resistance and Molecular Characteristics of Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus
por: Liang, Jin, et al.
Publicado: (2023)

Molecular epidemiology of heteroresistant vancomycin-intermediate Staphylococcus aureus in Brazil
por: Silveira, Alessandro Conrado de Oliveira, et al.
Publicado: (2015)

Novel single-nucleotide variations associated with vancomycin resistance in vancomycin-intermediate Staphylococcus aureus
por: Lin, Lee-Chung, et al.
Publicado: (2018)

Vancomycin (VAN) Combinations with Β-Lactams (BLs) against Methicillin-Resistant Staphylococcus aureus (MRSA), Heterogeneous Intermediate-Level Resistance to Vancomycin (hVISA) and Vancomycin-Intermediate Staphylococcus aureus (VISA)
por: Tran, Kieu-Nhi, et al.
Publicado: (2017)

Comparative Analysis of Virulence and Toxin Expression of Vancomycin-Intermediate and Vancomycin-Sensitive Staphylococcus aureus Strains
por: Jin, Ye, et al.
Publicado: (2020)

Vancomycin-intermediate Staphylococcus aureus in a home health-care patient.
por: Hageman, J C, et al.
Publicado: (2001)

Novel Mutation Sites in the Development of Vancomycin- Intermediate Resistance in Staphylococcus aureus
por: Wang, Yubing, et al.
Publicado: (2017)

Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
por: Shariati, Aref, et al.
Publicado: (2020)

The Role of β-Glycosylated Wall Teichoic Acids in the Reduction of Vancomycin Susceptibility in Vancomycin-Intermediate Staphylococcus aureus
por: Hort, Michael, et al.
Publicado: (2021)

Antimicrobial pharmacodynamics of vancomycin and disulfiram (Antabuse®) in Staphylococcus aureus
por: Chavva, Hasitha, et al.
Publicado: (2023)

Synergy of Arbekacin-based Combinations Against Vancomycin Hetero-intermediate Staphylococcus aureus
por: Lee, Ji-Young, et al.
Publicado: (2006)

In vitro selection of Staphylococcus aureus mutants resistant to tigecycline with intermediate susceptibility to vancomycin
por: Herrera, Melina, et al.
Publicado: (2016)

Draft Genome Sequences of Vancomycin-Intermediate Staphylococcus aureus Strains in South Korea
por: Kim, Jung Wook, et al.
Publicado: (2016)

Apt (Adenine Phosphoribosyltransferase) Mutation in Laboratory-Selected Vancomycin-Intermediate Staphylococcus aureus
por: Lamichhane-Khadka, Reena, et al.
Publicado: (2021)

Cell wall thickness and the molecular mechanism of heterogeneous vancomycin‐intermediate Staphylococcus aureus
por: Cui, J., et al.
Publicado: (2021)

Cervimycin-Resistant Staphylococcus aureus Strains Display Vancomycin-Intermediate Resistant Phenotypes
por: Dietrich, Alina, et al.
Publicado: (2022)

Identification of Lysine Succinylome and Acetylome in the Vancomycin-Intermediate Staphylococcus aureus XN108
por: Tan, Li, et al.
Publicado: (2022)

Discriminatory Indices of Typing Methods for Epidemiologic Analysis of Contemporary Staphylococcus aureus Strains
por: Rodriguez, Marcela, et al.
Publicado: (2015)

Vancomycin Resistance in Staphylococcus aureus 
por: McGuinness, Will A., et al.
Publicado: (2017)

Complete Genome Sequence of Vancomycin-Intermediate Staphylococcus aureus Strain MI (HIP5827)
por: Hishinuma, Tomomi, et al.
Publicado: (2016)

Antibiotic Exposure Leads to Reduced Phage Susceptibility in Vancomycin Intermediate Staphylococcus aureus (VISA)
por: McCallin, Shawna, et al.
Publicado: (2022)

Evidence from an In Vitro Study: Is Oxacillin Plus Vancomycin a Better Choice for Heteroresistant Vancomycin-Intermediate Staphylococcus aureus?
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2018)

A vancomycin resistance-associated WalK(S221P) mutation attenuates the virulence of vancomycin-intermediate Staphylococcus aureus
por: Rao, Yifan, et al.
Publicado: (2021)

Staphylococcus aureus viewed from the perspective of 40,000+ genomes
por: Petit, Robert A., et al.
Publicado: (2018)

Vancomycin Susceptibility within Methicillin-resistant Staphylococcus aureus Lineages
por: Howe, Robin A., et al.
Publicado: (2004)

Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patients
por: Maor, Yasmin, et al.
Publicado: (2009)

Detection of Staphylococcus aureus with an intermediate profile to vancomycin (VISA) isolate from Santa Maria, RS
por: Marques, Jaciane Baggiotto, et al.
Publicado: (2013)

Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients
por: Koh, Young Rae, et al.
Publicado: (2016)

Detection of heterogeneous vancomycin-intermediate Staphylococcus aureus: A preliminary report from south India
por: Amberpet, Rajesh, et al.
Publicado: (2019)

Alpha-amyrin as an anti-biofilm agent against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus
por: Chung, Pooi Yin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hdmpu2g74cs1ubamqkbbd9pqa3